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ABSTRACT 
 
Background: Bainbridge–Ropers syndrome (BRPS) is a recently described developmental 
disorder caused by de novo truncating mutations in the Additional sex combs-like 3 (ASXL3) 
gene. To date there have been fewer than ten reported patients.  
 
Objectives: Here we delineate the BRPS phenotype further by describing a series of twelve 
previously unreported patients identified by the Deciphering Developmental Disorders 
(DDD) study.  
 
Methods: Trio-based exome sequencing was performed on all twelve patients included in 
this study which found a de novo truncating mutation in ASXL3. Detailed phenotypic 
information and patient images were collected and summarised as part of this study. 
 
Results: By obtaining genotype: phenotype data, we have been able to demonstrate a second 
mutations cluster region within ASXL3. This report expands the phenotype of older patients 
with BRPS; common emerging features include severe intellectual disability (12/12), poor/ 
absent speech (12/12), autistic traits (9/12), distinct face (arched eyebrows, prominent 
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forehead, high-arched palate, hypertelorism and down-slanting palpebral fissures), (9/12), 
hypotonia (12/12) and significant feeding difficulties (12) when young. 
 
Discussion: Similarities in the patients reported previously in comparison to this cohort 
included their distinctive cranio-facial features, feeding problems, absent/limited speech, and 
intellectual disability. Shared behavioural phenotypes include autistic traits, hand-flapping, 
rocking, aggressive behaviour, and sleep disturbance.  
 
Conclusions: This series expands the phenotypic spectrum of this severe disorder and 
highlights its surprisingly high frequency. With the advent of advanced genomic screening, 
we are likely to identify more variants in this gene presenting with a variable phenotype 
which this study will explore. 
 
INTRODUCTION 
Large scale whole exome sequencing projects such as the Deciphering Developmental 
Disorders (DDD) Project have led to the discovery of a number of new genes underlying 
developmental disorders [1,2]. A reverse-genetics approach has proven particularly important 
for the discovery of disorders like Bainbridge–Ropers syndrome (BRPS), whose main clinical 
features are non-specific, especially when looked at in isolation or with a small number of 
patients. De novo mutation status is the first clue to potential pathogenicity of a given variant 
and such mutations are known to constitute a significant proportion of the underlying causes 
of moderate and severe intellectual disability (ID) [3]. 
  
ASXL1, ASXL2 and ASXL3 are human homologs of the Drosophila additional sex combs (asx) 
gene that encode putative polycomb proteins and are likely to act as histone 
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methyltransferases in complexes with other proteins [4]. Polycomb group proteins are 
implicated in embryogenesis and carcinogenesis through transcriptional regulation of target 
genes; the ASXL1 gene is thought to be one of the most frequently mutated genes in 
malignant myeloid diseases; ASXL is a scaffold protein interacting with methyltransferases 
and additional proteins of the epigenetic machinery [5,6]. Truncating mutations in ASXL1 
have been reported in association with Bohring-Opitz syndrome (BOS) which has phenotypic 
overlap with BRPS [7]. More recently, truncating mutations in ASXL2 were reported in 
association with a newly recognisable clinical phenotype [8]. 
 
Srivastava et al., 2016 showed that ASXL3 interacts with BAP1, a hydrolase that removes 
mono-ubiquitin from histone H2A lysine 119 (H2AK119Ub1) as a component of the 
Polycomb repressive deubiquitination (PR-DUB) complex [9]. The authors observed a 
significant increase in H2AK119Ub1 in ASXL3 patient fibroblasts, highlighting an important 
functional role for ASXL3 in PR-DUB mediated deubiquitination. Transcriptome analysis 
revealed >500 genes differentially expressed in ASXL3 patient fibroblasts relative to controls, 
and these genes were enriched for those involved with molecular processes impacting 
transcriptional regulation, development and proliferation. 
 
ASXL3 is expressed in similar tissues to ASXL1 including brain, spinal cord, kidney, liver, 
and bone marrow, but at a lower level [10]. The high correlation of expression patterns 
between ASXL1 and ASXL3 may account for some of the shared phenotypic features. 
 
Heterozygous, de novo loss-of-function mutations in ASXL3, underlying the Bainbridge–
Ropers syndrome (BRPS: OMIM #615485) have been described in 9 individuals to date [9, 
11-13]. The major phenotypic features described in the majority of patients so far include 
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failure to thrive, global developmental delay, feeding problems, hypotonia, dysmorphic 
features, profound speech delay and intellectual disability. Here we present genetic and 
phenotypic information on 12 previously unreported individuals with de novo truncating 
mutations in ASXL3, all of which were detected via the trio exome sequencing carried out by 
the DDD Project.  Additional clinical features of BRPS are likely to emerge with 
identification of additional patients through such large scale exome sequencing projects as 
described here. 
 
METHODS 
EXOME SEQUENCING 
In all twelve individuals identified via the DDD study, trio-based exome sequencing was 
performed on the affected individual and their parents, as previously described by Wright et 
al., 2014.  Each affected individual has also had a high-resolution analysis for copy number 
abnormalities using array-based comparative genomic hybridization (aCGH).  Putative de 
novo mutations were identified from exome data using DeNovoGear software  as described 
by Ramu et al., 2013 and were validated using targeted Sanger sequencing [14,15]. 
 
All recruited patients had the following de novo heterozygous pathogenic mutations 
identified which confirmed the diagnosis of Bainbridge-Ropers syndrome (OMIM: 615485): 
Patient 1: c.4330C>T, p.(Arg1444*) 
 Patient 2: c.1201del, p.(Ala401GlnfsTer8)  
Patient 3: c.1074T>A, p.(Tyr358*) 
Patient 4: c.4144C>T, p.(Gln1382*) 
Patient 5: c.1783C>T, p.(Gln595*) 
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Patient 6: c.3355dup, p.(His1119Profs*7) 
Patient 7: c.1082dup, p.(Leu362AlafsTer23)  
Patient 8: c.3635T>G, p.(Leu1212*)  
Patient 9: c. 3127_3128dup, p.(Gly1045Valfs*99) 
Patient 10: c.3178dup, p.(Arg1060Profs*50) 
Patient 11: c.1484insTGAA, p.(Asp497*)  
Patient 12: c.1491dup, p.(Asn498*)  
Mutation nomenclature is according to HGVS recommendations (http://varnomen.hgvs.org/), 
and is based on reference transcript NM_030632.2. 
 
PATIENT ASCERTAINMENT 
All twelve individuals were recruited via UK NHS Regional Genetics Services onto the 
Deciphering Developmental Disorders (DDD) Project (www.ddduk.org). As part of that 
study, patient and parental samples receive array CGH and exome sequencing analysis and 
findings of potential clinical significance are reported back to recruiting clinical geneticists. 
Any significant findings are usually validated by an accredited UK NHS diagnostic genetics 
laboratory before being reported to patients and their families; mutations described in this 
paper have been validated as such. Patient phenotype information was provided to the authors 
via Clinical Geneticists from several UK NHS genetics services. See Table 1 for a summary 
of the clinical and molecular findings. 
 
RESULTS 
ASXL3 MUTATIONS 
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Previously reported truncating ASXL3 mutations cluster mainly within the 5’ end of exon 11 
between codons 404 and 659. This region lies in-between the N-terminal protein scaffolding 
functional domains of the gene and the C-terminal chromatin/DNA-targeting functional 
domain. Srivastava et al., 2016 reported two mutations significantly 3’ to this main cluster 
region, at codons 1122 and 1444 [9]. One of the patients (Patient 1) within our cohort carries 
the same c.4330C>T p.(Arg1444*) mutation as the patient reported by Srivastava et al, 2016 
suggesting it as a possible recurrent mutation.  
 
Among our cohort, 5/12 (Patients 2, 3, 7, 11, 12) of the mutations could be described as 
occurring within the originally reported mutation cluster region, 1/12 (Patient 5); c.1783C>T, 
p.(Gln595*),  maps more 3', and the remaining 6 (Patients 1, 4, 6, 8, 9, 10) lie further 
downstream within the more 3’ region, reported by Srivastava et al, 2016, which could be 
considered as a distinct mutation cluster region, extending between codons 1045 and 1444 
[9]. All these mutations are publicly available on www.ddduk.org.  
 
PATIENT PHENOTYPES 
 
Antenatal history and birth: Polyhydramnios and concerns regarding poor growth were 
noted in 1/12 but otherwise unremarkable. For 9/12 patients, a caesarean section was 
performed, mostly due to breech presentation. All 12 patients had an average birth weight and 
apart from 4/12 patients who were admitted to the Neonatal unit for respiratory difficulties/ 
apnoea, the remainder neonatal period was uneventful. 
 
Feeding problems: Consistent with previous reports, 9/12 patients were reported to have 
significant feeding problems, often including gastro-oesophageal reflux, requiring 
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intervention in the form of nasogastric tube feeding, fundoplication. The majority were 
described as having failure to gain weight with poor appetite.  
 
Growth: Patients reported here had consistent poor growth with weight and height below the 
0.4th centile and relative microcephaly (7/12). This is in keeping with previously reported 
literature. 
 
Craniofacial features: 9/12 have a high-arched palate, distinctive facial dysmorphism as 
described below (Figure 1). 
 
Dysmorphic features:  10/12 had down-slanting palpebral fissures and 2 had up-slanting 
palpebral fissures; both have previously been reported but down-slanting seems to be more 
common. A long, tubular nose with a prominent nasal bridge is apparent in most. Most of the 
individuals have a broad nasal tip with low columella. The mouth is wide with full (everted) 
lower lip. Hypertelorism, a narrow head shape with prominent forehead, ‘pencilled’ and/or 
high-arched eyebrows and crowded teeth were also common features. 
 
Other significant features: 12/12 had significant hypotonia, 7/12 had strabismus of varying 
severity. 3 patients had seizures, previously reported in 2 other ASXL3 patients. Patient 2 had 
scoliosis requiring surgery. 3 patients had arachnodactyly, not previously reported in any 
ASXL3 patients. 3/12 appears to have a Marfanoid habitus with arachnodactyly, tall stature, 
pes planus and scoliosis. 
 
Intellectual Disability: The level of intellectual disability ranged from moderate to profound 
but more likely at the severe end of the spectrum. All patients had ID of varying degree; 
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generally severe. Most were very delayed in walking unassisted and 2 remained entirely non-
ambulant. 9/12 patients were entirely non-verbal, including Patient 2 at 22 years of age. 9/12 
patients had either formally diagnosed autism or autism spectrum disorder, or were described 
as having autistic features. 3 patients exhibited hand-flapping, rocking. All the patients were 
in a special needs school requiring significant help. 
 
Relevant negative findings: Seizures does not appear to be a major feature, seen in only 
3/12 patients and generally well-controlled absence seizures; MRI-brain imaging only 
showed non-specific features with white matter changes (3/12) and vermis hypoplasia (1/12) 
which is relevant given the significance of intellectual disability in this cohort of patients. 
 
DISCUSSION 
The recently described Bainbridge–Ropers syndrome (BRS; OMIM # 615485), associated 
with de novo truncating mutations in the Additional sex combs-like 3 (ASXL3) gene (OMIM * 
615115), shows phenotypic overlap with Bohring-Opitz syndrome, which is associated with 
de novo truncating mutations in ASXL1 (OMIM * 612990). Bohring-Opitz syndrome (BOS; 
OMIM # 605039) is characterised by distinct craniofacial features and posture, severe 
intellectual disability, feeding problems, small size at birth, and failure to thrive. 
 
Bainbridge et al. 2013 reported a series of four unrelated probands with de novo, 
heterozygous, truncating mutations in ASXL3, sharing similar phenotypes, including severe 
feeding difficulties, failure to thrive, and neurologic abnormalities with significant 
developmental delay [11]. More recently, truncating mutations in ASXL2 were reported as 
being associated with a newly recognisable syndrome with overlapping features to BOS and 
BRPS [8]. In this report, the authors described six unrelated patients with de novo truncating 
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mutations in ASXL2 with shared clinical features including intellectual disability, 
macrocephaly, distinct facies, facial nevi, feeding difficulties and hypotonia. Comparison of 
patients reported in this with BRPS shows the facial dysmorphism to be more similar to BOS 
with macrocephaly, arched eyebrows, synophrys and facial nevi rather than with BRPS. 
Other distinguishing features included macrocephaly, congenital heart disease, structural 
brain malformations and seizures in these patients, which differs to the BRPS cohort. 
However, there are emerging similarities within this group of conditions, including 
hypotonia, feeding difficulties and intellectual disability, which will become more apparent 
as more patients are reported with ASXL2 mutations. 
 
To date there have been fewer than ten reported patients with de novo truncating ASXL3 
mutations. Emerging similarities include, distinctive cranio-facial features with arched 
eyebrows, prominent forehead, high-arched palate, hypertelorism with down-slanting 
palpebral fissures; significant feeding difficulties needing support; profound/ severe 
intellectual disability; emerging behavioural phenotype consisting of autistic traits, hand-
flapping, rocking, aggressive behaviour, sleep issues with absent/ poor speech. Table 1 
provides a comprehensive summary of reported features in this cohort: predominant features 
in the phenotype are normal pregnancy, higher incidence of caesarean section due to breech 
presentation, relative microcephaly, significant feeding difficulties, facial dysmorphism , 
high-arched palate, strabismus, hypotonia, skeletal features including a Marfanoid habitus 
(especially in the older patients), severe intellectual disability with poor/ absent speech, 
autistic traits, need for special education. Seizures, structural malformations of internal 
organs including the brain, kidneys do not appear to be a predominant part of their 
phenotype. However, this is likely to be revised/ expanded as more patients are described 
with BRPS. 
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There is a wide age range (4-22 years), this being the first report of older patients with BRPS. 
The older patients in this cohort all have moderate to severe ID, autistic features, attended a 
special needs school and are in assisted living. Seizures are a component but not a 
predominant part of their phenotype and they do not appear to have any major structural 
associations with this diagnosis as they have grown older. The behavioural phenotype 
appears to be in keeping with other severe developmental disorders with absent/ poor speech, 
periods of agitation, frustration and poor sleep. 
 
Though Bainbridge-Ropers syndrome (BRPS) is likely to remain a challenging syndrome to 
recognise clinically, this cohort of patients has enabled further delineation and expansion of 
the phenotype. Results of analysis of the first several thousand patient trios within the DDD 
Project suggests that de novo ASXL3 mutations are among the more common underlying 
causes of disease within the DDD cohort (at time of writing, ASXL3 ranks number 12 out of 
the top 20 genes in which a pathogenic de novo mutation has been found), and therefore it is 
expected that there will be many more BRPS patients diagnosed in the near future, further 
defining the associated clinical spectrum.  
 
Our cohort has also firmly established a second, 3’ mutational cluster region within ASXL3 
which may be of significance to disease mechanism. In regards to this, an ASXL3 mRNA 
transcript carrying the c.1448dupT truncating mutation has previously been shown to be 
prone to nonsense-mediated decay, with resultant reduction in expression of ASXL3 [6]. 
Consistent with previous reports and consistent with this disease mechanism, the cohort of 
patients described here do not show a correlation between phenotypic features or severity and 
mutation position. It has previously been noted that several truncating mutations in ASXL3 
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are described in databases composed of sequence variants from phenotypically normal 
individuals (see Figure 2). To date, there are 4 such mutations within the ExAC dataset, each 
identified within only one individual within the dataset, and they occur both 5’ to the original 
5’ mutational cluster region (MCR) and 3’ to the new 3’ cluster region, and also in between 
the two cluster regions. The explanation for these mutations is as yet uncertain. 
 
We have also been able to collect phenotypic data from several patients with previously 
unreported missense variants in ASXL3 (including p.Ser86Ala, p.Lys1026Asn, p.Arg933Trp 
and p.Ser720Cys). However, in each case the variants were inherited from clinically 
unaffected parents and the patients had a very dissimilar presentation in comparison to the 
clinical presentation associated with ASXL3 loss-of-function mutations. Without further 
investigation it cannot be ruled out that these variants are of clinical significance, however it 
is unlikely that they are the sole cause of the phenotype observed in these patients. It is 
possible that they represent rare polymorphisms. In support of this, all of these variants are 
found, albeit at low frequency, within healthy control populations (Exome Aggregation 
Consortium, Cambridge, MA, URL: http://exac.broadinstitute.org).  
 
Ropers et al., 2015 previously highlighted the presence of truncating mutations in ASXL3 and 
several other dominant genes for intellectual disability or related disorders, within healthy 
control populations, suggesting the possibility of incomplete penetrance for truncating 
mutations within these genes [14]. This included ASXL1, for which 56 such mutations were 
found within the ExAC dataset. 
 
Whilst it cannot be entirely ruled out that truncating ASXL3 mutations exhibit incomplete 
penetrance, the number of such mutations (four) found within the ExAC data is still relatively 
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small compared to ASXL1 and the other genes examined, and the list of reported patients with 
ASXL3 truncating mutations that have a Bainbridge-Ropers syndrome consistent phenotype is 
growing.  
 
Therefore, it seems reasonable that all four of these ASXL3 mutations may be accounted for 
by the various other explanations that Ropers put forward, for example, two of the mutations 
occur at the extreme 3’ end of the gene, and may therefore escape nonsense mediated decay 
(NMD), retaining protein activity.  Bainbridge et al., 2013 suggested that mutations may arise 
post-zygotically or during later embryogenesis and thus the phenotypic variability or 
incomplete penetrance may be explained by mosaicism [11]. With the increasingly wider 
access of high read-depth exome sequencing for genetic diagnosis of children with 
developmental disorders it seems likely that this question will eventually be answered as 
more data emerges.  
 
CONCLUSIONS 
In this series, we report 12 patients with ASXL3 loss-of-function de novo variant and expand 
the phenotype of Bainbridge-Ropers syndrome. New specific associated clinical features 
have become apparent, such as hypotonia, Marfanoid habitus, and arachnodactyly. This 
cohort is consistent with previously reported patients with regards to the facial features and 
also confirms pertinent negative features such as lack of significant findings on brain 
imaging, and lack of seizures. This research further reiterates the power of whole exome 
studies in conjunction with a detailed clinical phenotype in providing an explanation for our 
patient’s difficulties and a unifying diagnosis for their concerns.  
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FIGURE AND TABLE LEGENDS 
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Figure 1: Facies of individuals with ASXL3 loss-of-function mutations reported herein 
demonstrating down-slanting palpebral fissures, a long, tubular nose with a prominent nasal 
bridge is apparent in most. Most individuals have a broad nasal tip with low columella. The 
mouth is wide with full (everted) lower lip; hypertelorism, a narrow head shape with 
prominent forehead, ‘pencilled’ and/or high-arched eyebrows. 
Figure 2. Map of ASXL3 mutations reported to date. Mutation nomenclature according to 
HGVS guidelines (http://varnomen.hgvs.org/) using NCBI reference  Transcript 
NM_030632.3).  
Table 1: Clinical features of twelve previously-unreported patients with ASXL3 loss-of-
function mutations reported herein in comparison to previously reported patients with 
Bainbridge-Ropers syndrome. 
Supplementary section containing a detailed clinical summary of all patients reported here. 
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(2013)* Patient 2 
Bainbridge et al., 
(2013)* Patient 3 
Bainbridge et al., 
(2013)* Patient 4 
Dinwiddie et al., 
(2013) 
Srivastava et al., 
(2016) 
Patient 1 
Srivastava et al., 
(2016) Patient 2 
Srivastava et al., 
(2016) Patient 3 
Hori et al., 2016 Patient 1 
Decipher ID NA NA NA NA NA NA NA NA NA 274629 
ASXL3 Variant c.1210C>T, 
p.Gln404* 
c.1396C>T, 
p.Gln466*  
 
c.1422dup, 
p.Glu475*  
 
c.1978_1981del, 
p.Asp660Asnfs*16 
c.1897_1898delC
A, 
p.Gln633Valfs*1 
c.4330C>T, 
p.(Arg1444*) 
c.3664C>T, 
p.Q1122X 
c.1448dupT, 
p.Thr484Asnfs*5 
c.3039+1G>A 
c.4330C>T 
p.(Arg1444*) 
Age NR 3yrs 5yrs 3.5yrs 6yrs 5.5yrs 4yrs 13m 5yrs 
21yrs 
Sex NR M F F F F M M F M 
Height -4.5 to -5SD <1% Normal Reduced 10th- 25th  24th  NR NR -3 SD(<<0.4th) 50th 
Weight -4.5 to -5SD <1% Normal Reduced 10th – 25th  24th  NR NR -3.4SD (<0.4th) 75th-91st  
OFC -4.5 to -5SD <1% Normal Reduced 3rd  4th  NR NR -3 SD (<<0.4th) 25th  
Pregnancy IUGR Normal Normal Normal Normal IUGR Normal Normal Normal Normal 
Birth Normal Breech CS Normal CS; Breech; BW- 
1.88kg 
Normal; BW- 2.25kg Normal; BW- 
3.4kg 
Normal; BW- 3.1kg Normal; BW- 
2.43kg 
Elective CS ; breech; 
BW-3.7kg 
Neonatal Unit NR NR NR NR Yes No No No Yes, 2/52 Yes, 5/7  
Gestation Term Term Term Term 34 weeks Term Term Term Term Term 
Feeding 
Difficulties 
Yes Yes No Yes Yes Yes Yes Yes Yes No 
Cranio-facial 
features 
Arched, thin 
eyebrows, 
microcephaly 
Arched, thin 
eyebrows, 
microcephaly 
Frontal bossing, 
short nose 
Arched eyebrows, 
hypoplastic ale nasi 
Microcephaly, 
trigonocephaly, 
epicanthic folds 
Low-set ears, short 
nose, micrognathia 
Anteverted nares, 
small chin 
NAD Prominent 
forehead, thick 
eyebrows 
Long tubular nose, thin 
upper lip 
Downslanting 
palpebral 
fissure 
NR Yes Yes Yes No Yes Yes Yes Yes 
Yes 
Palate NR NR NR Narrow, high-arched Normal NR NR NR NR High-arched 
Strabismus NR NR   No No No No Yes No 
Hypotonia Yes Yes Yes Yes Yes Yes Yes Yes No Yes 
Marfanoid 
habitus 
NA NR NR NR No No No No No Yes 
Skeletal 
features 
Ulnar deviation Ulnar deviation Normal Ulnar deviation Metopic 
synostosis 
NR Ulnar deviation No camptodactyly 
arachnodactyly 
ID Severe, died at 
9/12 
Severe Moderate Severe Severe Moderate Moderate Moderate Moderate Moderate 
Seizures NR NR NR NR No Yes No Yes No 
No 
Autism/ ASD NR NR NR NR Yes NR NR NR Yes Yes (and Tourette's 
syndrome) 
Structural 
anomalies 
NR NR NR White matter 
changes on MRI 
Pulmonary 
stenosis 
White matter changes 
on MRI 
Vermis hypoplasia White matter 
changes on MRI 
No No 
Dev. Outcome Delayed Delayed Delayed Delayed Delayed Delayed Delayed Delayed Delayed Delayed 
Speech and 
language 
NA Absent Absent Absent Absent Absent Few words Absent Delayed, few 
words 
Delayed, needed 
speech therapy 
Behaviour NA NR NR NR Poor sleep; 
aggressive 
NR Aggressive NR Moderate autism, 
poor sleep 
Tourette's syndrome, 
autistic traits 
Hand flapping NA NR NR NR NR NR NR NR NR Yes 
Educational 
support 
NR NR NR NR NR NR NR NR NR Yes: SEN 
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 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6  Patient 7 Patient 8 Patient 9 Patient 10  Patient 11  Patient 12  R/V 
Decipher ID 275029 274593 278695 261513 265854 271912 275860 265908 259240 272591 208772  
ASXL3 
Variant 
c.1201del 
p.(Ala401fs) 
c.1074T>A 
p.(Tyr358*)  
c.4144C>T 
p.(Gln1382*)  
c.1783C>T 
p.(Gln595*) 
c.3355dup 
p.(His1119fs) 
c.1082dup 
p.(leu362fs) 
c.3635T>G 
p.(Leu1212*) 
c.3127_3128dup 
p.(Gly1045fs) 
c.3178dupC, 
p.(Arg1060fs)  
c.1484insTGAA, 
p.(Asp497Ter) 
c.1491dup 
p.(Asn498*) 
 
Age 22yrs 6yrs 6yrs 9yrs 6yrs 10yrs 20yrs 4yrs 3mths 9yrs 19yrs 8yrs  
Sex F F F M M Male Female Female Male Female Male  
Height <0.4th  25th  9th  25th  75th-91st  50th  2nd  50th  25th   9th  50th   
Weight 0.4th  50th  <0.4th    25th-50th  50th  >99th  <0.4th  0.4th  9th   2nd  25th   
OFC <0.4th  <0.4th  0.4th-2nd    0.4th-2nd  0.4th  <25th  <0.4th  0.4th  <0.4th  0.4th  50th   
Pregnancy 
Polyhydramnios Normal Normal Normal Normal Normal IVF (twin well) Normal 
Mild renal pelvis 
dilatation at 20/40, 
resolved postnatally 
Normal Normal 
11/12 
Birth Em CS; breech; BW- 
2.98kg 
Em CS; BW- 
3.12kg 
Normal; BW- 
2.7kg 
Em CS; breech; 
BW- 3.5 kg Induced Normal Induced, Em CS El CS; breech 
El CS; extended 
breech; BW- 3.4kg 
Normal; BW- 3.4 
kg El CS; breech 
9/12 
CS 
Neonatal Unit Yes, 5/7  No No No Yes, apnoea No No No No Febrile No 4/12 
Gestation Term Term Term 39/40 42/40 41 weeks 40 weeks 38/40 38/40 40 weeks 38 weeks  
Feeding 
Difficulties Yes: Poor 
suck/swallow, GOR, 
fundoplication at 3yrs 
No 
Yes: Hx of 
GER, feeding 
issues, poor 
appetite 
Yes: Stopped 
breast feeding at 
4mths due to poor 
weight gain 
Yes: gastrostomy 
fed; GOR; 
fundoplication 
No Yes: Severe, NG fed for 2 yrs Yes Yes: GOR; FTT 
Yes: frequent 
vomiting as a 
baby 
Yes 
9/12 
Cranio-facial 
features hypertelorism, 
hirsutism, finely 
'pencilled' eyebrows 
hypertelorism, 
down-slanting 
palpebral fissures 
thick eyebrows, 
prominent 
forehead, high 
nasal bridge, 
deep set eyes 
posteriorly rotated 
ears, dental 
overcrowding, 
long jaw 
prominent nasal 
bridge, tongue tie, 
micrognathia 
synophrys, finely 
'pencilled' eyebrows, 
micrognathia, 
prominent central 
incisors 
scaphocephaly, 
prominent nasal bridge, 
mild synophyrus, 
crowded teeth, high 
palate 
_ 
long face with 
slightly upslanted 
palpebral fissures 
and twin hair crowns 
Extremely slim 
and long limbed _ 
9/12 
Downslant pf No Yes Yes No No Yes No No No Yes Yes 6/12 
Palate 
High-arched Narrow, high-
arched NAD High-arched High-arched NAD 
High-arched, bifid 
uvula Normal High-arched 
High-arched, 
narrow palate High-arched 
9/12 
Strabismus Yes, divergent  Yes Yes No Yes No Bilateral, 
convergent/divergent Yes No No Yes 
7/12 
Hypotonia Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 12/12 
Marfanoid 
habitus No No Yes No No No No No _ Yes No 
3/12 
Skeletal 
features 
Camptodactyly 4th 
fingers, short distal 
phalanx of thumbs, 
scoliosis  
hyperflexible 
elbows arachnodactyly No No No 
narrow small feet, pes 
planus No postural scoliosis 
Malar hypoplasia, 
long slim hands 
and feet 
No 
7/12 
ID Profound Moderate Severe Severe Severe Moderate/Severe Severe Moderate _ Severe Severe 12/12 
Seizures 
Yes; absences No No No No No Possible absences 6y; GTCS from 11y No No 
GTCS in 
childhood Yes 
3/12 
Autism/ ASD Likely; not formal No ASD Likely (no formal Dx) No Autism  Autism (Dx 6yrs) No ASD, SDP, ADD  
Likely (no formal 
Dx) Yes 
9/12 
Structural 
anomalies unilateral choanal 
stenosis No No No No No 
Bifid nail, 
laryngomalacia, 
intestinal malrotation 
No No No No 
2/12 
Speech and 
language only noises v. delayed v delayed 
makes noises and 
uses Makaton 
Communicates by 
looking at objects 
Non-verbal, displays 
comprehension 
Only simple sounds, no 
words: uses PECS delayed Uses PECS _ 
no expressive 
language 
12/12 
Behaviour Autistic traits, 
hyperventilates No  autistic traits No 
Periodic agitation 
with self-harming 
Poor sleep; difficult 
behaviour 
Frustrated; hand 
flapping when upset _ Pica; sleep disorder  Grunting; bruxism generally placid 
9/12 
Hand 
flapping Yes No No No No No Yes 
shakes and claps 
hands 
head rocking and 
clicking _ Yes 
3/12 
Educational 
support Yes: special school 
Yes: special 
school 
Yes: special 
school 
Yes: special 
school Yes: special school Yes: special school Yes: special school 
Yes: special 
school Yes: SEN Yes: SEN 
Yes: special 
school 
12/12 
M: Male; F: Female; NR: Not reported; NA: Not applicable; PD: Palpebral fissures; ASD: Autism spectrum disorder; ID: Intellectual disability; Dx: Diagnosis; NAD: No abnormality detected; BW: Birth weight; Em CS: Emergency caesarean section; El CS: Elective caesarean section; SEN: Special educational needs; GOR: gastro-oesophageal reflux; FTT: Failure to thrive; GTCS: 
generalised tonic-clonic seizures; PECS: Picture exchange communication system; -: Not known; R/V: review summary 
